

Nplate®

Physician Billing and Coding Information

Contact Amgen SupportPlus at (866)264-2778, Monday - Friday
9:00 am - 8:00 pm EST to learn how Amgen can help. Or visit
AmgenSupportPlus.com.



INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Item	Coding Information (HCPCS ¹ /CPT ² /ICD-10-CM ³)	Notes
Nplate®	<p>J2802, injection, romiplostim, 1 mcg</p> <p>JW/JZ Modifiers: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers.⁴</p>	<p>Effective Jan 1, 2025, the HCPCS has changed from J2796 to J2802, injection, romiplostim, 1 mcg.</p> <p>Healthcare providers should ensure Billing Service Units (Box 24G) are appropriately billed in multiples of 1 unit = 1 mcg.</p> <p>Nplate® is supplied in single-use vials containing 125 mcg, 250 mcg and 500 mcg deliverable romiplostim</p> <p>The NDC numbers for Nplate®, in the 11-digit format, are as follows:</p> <ul style="list-style-type: none"> - 125-mcg vial: 55513-0223-01 - 250-mcg vial: 55513-0221-01 - 500-mcg vial: 55513-0222-01 <p>Additional step may be required if billing ≥ 1,000 units in Box 24 G. Follow payer or billing software guidance which may require billing on two lines.</p>
Administration	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Office visit	Relevant Evaluation and Management (E&M) code ^{*,†}	See payer guidelines
Diagnosis/Condition	Appropriate ICD-10-CM code(s) for patient condition	<p>Example:</p> <p>D69.3 Immune thrombocytopenic purpura</p>

IMPORTANT SAFETY INFORMATION

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

- In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
- Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Please see additional Important Safety Information on page 4.



The CMS 1500 for Physician Office

Sample CMS 1500 Form — Physician Office Administration

HEALTH INSURANCE CLAIM FORM										CARRIER	
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12										PICA	
1. MEDICARE (Medicare#) <input type="checkbox"/> MEDICAID (Medicaid#) <input type="checkbox"/> TRICARE (ID#/DoD#) <input type="checkbox"/> CHAMPVA (Member ID#) <input type="checkbox"/> GROUP HEALTH PLAN (ID#) <input type="checkbox"/> FECA BLK LUNG (ID#) <input type="checkbox"/> OTHER (ID#) <input type="checkbox"/>										1a. INSURED'S I.D. NUMBER (For Program in Item 1)	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, John D				3. PATIENT'S BIRTH DATE (MM DD YY) XX XX XX SEX <input type="checkbox"/> M <input type="checkbox"/> F		4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, John D					
5. PATIENT'S ADDRESS (No., Street) 5555 Any Street				6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>		7. INSURED'S ADDRESS (No., Street)					
CITY Anytown		STATE AS		8. RESERVED FOR NUCC USE		CITY		STATE			
ZIP CODE 01010		TELEPHONE (Include Area Code) (XXX) XXX-XXXX		9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)		10. IS PATIENT'S CONDITION RELATED TO:		11. INSURED'S POLICY GROUP OR FECA NUMBER			
a. OTHER INSURED'S POLICY OR GROUP NUMBER		b. RESERVED FOR NUCC USE		c. RESERVED FOR NUCC USE		a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO		a. INSURED'S DATE OF BIRTH (MM DD YY) <input type="checkbox"/> M <input type="checkbox"/> F			
b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO		c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO		10d. CLAIM CODES (Designated by NUCC)		b. OTHER CLAIM ID (Designated by NUCC)		c. INSURANCE PLAN NAME OR PROGRAM NAME			
PROGRAM NAME		13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.		14. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO <i>If yes, complete items 9, 9a, and 9d.</i>		15. OTHER DATE (MM DD YY)		16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION (FROM MM DD YY TO MM DD YY)			
17. INJURY, or PREGNANCY (LMP)		18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES (FROM MM DD YY TO MM DD YY)		19. ADDITIONAL CLAIM INFORMATION		20. OUTSIDE LAB?		21. DIAGNOSIS OR NATURE OF ILLNESS A. D69.3			
22. PRODUCT CODE (BOX 24D) Document use of product with J2802, injection, romiplostim, 1 mcg. JW/JZ DISCARD MODIFIER JW (discarded units) or JZ (no discarded units) modifier required in the Modifier box for Medicare Part B claims for drugs in single-use containers (e.g. JZ).		23. DIAGNOSIS CODE (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D.		24. SERVICE UNITS (BOX 24G) Report unit of service. 1 unit for J2802 corresponds to 1 mcg of Nplate®. (i.e., 500 service units = 500 mcg). Nplate® dose is 1-10 mcg/kg for ITP.		25. FEDERAL TAX I.D. NUMBER		26. TOTAL CHARGE			
27. PROCEDURE CODE (BOX 24D) Document product administration with appropriate CPT code. Use CPT code representing procedure performed, such as 96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.		28. AMOUNT PAID		29. Rsvd for NUCC Use		30. BILLING PROVIDER INFO & PH #		31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)			
32. SERVICE FACILITY LOCATION INFORMATION		33. BILLING PROVIDER INFO & PH #		34. BILLING PROVIDER INFO & PH #		35. BILLING PROVIDER INFO & PH #		36. BILLING PROVIDER INFO & PH #			

NOTE: Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

- In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
- Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

- Thrombotic/thromboembolic complications have resulted from increases in platelet counts with Nplate® use in the ITP population, including deep vein thrombosis (1.4%), pulmonary embolism (1.2%) and myocardial infarction (0.8%). Other thrombotic events including transient ischemic attack have been reported. These events have occurred regardless of platelet counts. Portal vein thrombosis has been reported in patients both with and without chronic liver disease receiving Nplate®.
- To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of $\geq 50 \times 10^9/L$.

Loss of Response to Nplate®

- Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
- Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

Adverse Reactions

Adult ITP

- In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions in adults with a $\geq 5\%$ higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
- The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.

Pediatric ITP

- The most common adverse reactions experienced by $\geq 5\%$ of patients receiving Nplate® with $\geq 5\%$ higher incidence in the Nplate® arm across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).
- In pediatric patients of age ≥ 1 year receiving Nplate® for ITP, adverse reactions with an incidence of $\geq 25\%$ in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
- In a long term, single arm, open label pediatric safety study, headache occurred in 78/203 patients (38%); the incidence rates of other adverse reactions were similar to those reported in the placebo-controlled studies.

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

Please [click here](#) for full Nplate® Prescribing Information, including Medication Guide.

*Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

†Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels when Modifier 25 is billed.

References: 1. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Recommendations Third Quarter, 2024 HCPCS Coding Cycle. <https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-3-2024-drugs-and-biologicals.pdf>. Accessed November 1, 2024. 2. American Medical Association (AMA). CPT 2021 Professional Edition. AMA; 2020. 3. CMS. ICD-10-CM Tabular list 2021. <https://www.cms.gov/medicare/icd-10/2021-icd-10-cm>. Accessed October 07, 2024. 4. CMS. Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy, available at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>. Accessed April 23, 2025.

The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this section be considered a guarantee of coverage or reimbursement for any product or service.

